Treatment of motor dysfunction in Parkinson's disease: An overview

Clinical Neurology and Neurosurgery

Volumn 107, Issue 4, 2005, Pages 269-281

  Thobois, Stéphane ^a   Delamarre Damier, Florence ^b   Derkinderen, Pascal ^c  

^a Service de Neurologie   (France)

^b ITG   (France)

^c CHU de Nantes   (France)

Author keywords

Deep brain stimulation; Dopamine agonists; IMAO B; Levodopa; Neuroprotection; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA TOCOPHEROL; AMANTADINE; APOMORPHINE; ASCORBIC ACID; BENSERAZIDE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA; LISURIDE; MONOAMINE OXIDASE B INHIBITOR; NEUROPROTECTIVE AGENT; OXIDOPAMINE; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; PROCYCLIDINE; RASAGILINE; REACTIVE OXYGEN METABOLITE; ROPINIROLE; SELEGILINE; TOLCAPONE; UBIDECARENONE;

ABDOMINAL PAIN; ANKLE EDEMA; ANTIOXIDANT ACTIVITY; BEHAVIOR DISORDER; BLEEDING; BRAIN DEPTH STIMULATION; CELL TRANSPLANTATION; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONTROLLED DRUG RELEASE; DEPRESSION; DISEASE COURSE; DIZZINESS; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG MEGADOSE; DYSKINESIA; DYSPEPSIA; ERYTHROMELALGIA; FACIAL NERVE PARALYSIS; HALLUCINATION; HEART MUSCLE FIBROSIS; HUMAN; HYPOTENSION; INFARCTION; INSOMNIA; INTRINSIC SYMPATHOMIMETIC ACTIVITY; LEG EDEMA; LIPID PEROXIDATION; LIVEDO RETICULARIS; LIVER TOXICITY; LOW DRUG DOSE; LUNG FIBROSIS; MORTALITY; MOTOR DYSFUNCTION; NAUSEA; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; ORTHOSTATIC HYPOTENSION; PALLIDOTOMY; PARKINSON DISEASE; RETROPERITONEAL FIBROSIS; REVIEW; SIDE EFFECT; SOMNOLENCE; SPEECH DISORDER; SUBSTANTIA NIGRA; SUBTHALAMOTOMY; SURGICAL TECHNIQUE; THALAMOTOMY; TREATMENT OUTCOME; TREMOR; VASOCONSTRICTION; VISUAL FIELD DEFECT; VOMITING; XENOGRAFT;

ANIMALS; ANTIPARKINSON AGENTS; DEEP BRAIN STIMULATION; DYSKINESIAS; GLOBUS PALLIDUS; HUMANS; NERVE GROWTH FACTORS; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; THALAMUS;

EID: 18844402610     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2005.02.002     Document Type: Review

References (171)

1. A. Samii, J.G. Nutt, and B.R. Ransom Parkinson's disease Lancet 363 9423 2004 1783 1793
2. A.H. Schapira, and C.W. Olanow Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions JAMA 291 3 2004 358 364
3. W. Maruyama, and M. Naoi Neuroprotection by (-)-deprenyl and related compounds Mech Age Dev 111 2-3 1999 189 200
4. W. Tatton, R. Chalmers-Redman, and N. Tatton Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B J Neural Transm 110 5 2003 509 515
5. Parkinson Study group Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring Levodopa Ann Neurol 39 1996 37 45
6. J.W. Tetrud, and J.W. Langston The effect of Deprenyl (Selegiline) on the natural history of Parkinson's disease Science 245 1989 519 522
7. V.V. Myllylä, K.A. Sotaniemi, J.A. Vuorinen, and E.H. Heinonen Selegiline as initial treatment in de novo parkinsonian patients Neurology 42 1992 339 343
8. C.W. Olanow, R.A. Hauser, L. Gauger, T. Malapira, W. Koller, and J. Hubble The effect of Deprenyl and Levodopa on the pregression of Parkinson's disease Ann Neurol 38 1995 771 777
9. S. Palhagen, E.H. Heinonen, J. Hägglund, T. Kaugesaar, H. Kontants, and O. Mäki-Ikola The Swedish Parkinson Study Group, Selegiline delays the onset of disability in de novo parkinsonian patients Neurology 51 1998 520 525
10. D.T. Dexter, C.J. Carter, F.R. Wells, F. Javoy-Agid, Y. Agid, and A. Lees Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease J Neurochem 52 1989 381 389
11. S. Fahn A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease Ann Neurol 32 Suppl. 1992 S128 S132
12. Parkinson Study Group Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease N Engl J Med 328 1993 176 183
13. J. Logroscino, K. Marder, L. Cote, M.X. Tang, S. Shea, and R. Mayeux Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study Ann Neurol 39 1996 89 94
14. D.E. Moorens, A. Grandinetti, C.I. Waslien, C.B. Park, G.W. Ross, and L.R. White Case-control study of idiopathic Parkinson's disease and dietary vitamin E intake Neurology 46 1996 1270 1274
15. W.L. Scheider, L.A. Hershey, J.E. Vena, T. Holmlund, J.R. Marshall, and T. Freudenheim Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease Mov Disord 12 1997 190 196
16. J.T. Greenamyre, T.B. Sherer, R. Betarbet, and A.V. Panov Complex I and Parkinson's disease IUBMB Life 52 3-5 2001 135 141
17. 10 in early Parkinson disease: evidence of slowing of the functional decline Arch Neurol 59 10 2002 1541 1550
18. G.C. Cotzias, P.S. Pappavasiliou, and R. Gellene Modification of parkinsonism-chronic treatment with L-DOPA N Engl J Med 280 1969 337 345
19. Levodopa: management of Parkinson's disease. Mov Disord, 2002;17(Suppl. 4):S23-37.
20. I. Libman, M.J. Gawel, R.J. Riopelle, and S. Bouchard A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients Can J Neurol Sci 14 4 1987 576 580
21. R.J. Riopelle Bromocriptine and the clinical spectrum of Parkinson's disease Can J Neurol Sci 14 3 Suppl. 1987 455 459
22. J.A. Cooper, H.J. Sagar, S.M. Doherty, N. Jordan, P. Tidswell, and E.V. Sullivan Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients Brain 115 Pt 6 1992 1701 1725
23. Parkinson's Disease Research Group in the United Kingdom Comparison's of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report Br Med J 307 1993 469 472
24. J.L. Montastruc, O. Rascol, J.M. Senard, and A. Rascol A randomised controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up J Neurol Neurosurg Psychiatr 57 1994 1034 1038
25. E. Herskovits, A. Yorio, and J. Leston Long term bromocriptine treatment in de novo parkinsonian patients Medicina (B Aires) 48 4 1988 345 350
26. M.A. Hely, J.G.L. Morris, W.G.J. Reid, D.J. O'Sullivan, P.M. Williamson, and D. Rail The Sydney multicenter study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa J Neurol Neurosurg Psychiatr 57 1994 903 910
27. O. Rascol, D.J. Brooks, A.D. Korczyn, P.P. de Deyn, C.E. Clarke, A.E. Lang F.T.S. group A 5 year study of the incidence of dyskinesia in patients with Parkinson's disease who were treated with ropinirole or levodopa N Engl J Med 342 2000 1484 1491
28. A. Schrag, and N. Quinn Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study Brain 123 Pt 11 2000 2297 2305
29. J.E. Ahlskog, and M.D. Muenter Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature Mov Disord 16 3 2001 448 458
30. Derkinderen P, Vidailhet M, Dyskinesia caused by L-DOPA. Rev Neurol (Paris), 2002;158(Spec no 1):S92-101.
31. W. Olanow, A.H. Schapira, and O. Rascol Continuous dopamine-receptor stimulation in early Parkinson's disease Trends Neurosci 23 10 Suppl. 2000 S117 S126
32. G. Block, C. Liss, J. Irr, D. Nibbelink The CR first Study group Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease Eur Neurol 37 1997 23 27
33. E. Dupont, E. Andersen, J. Boas, E. Boisen, R. Borgmann, and A.C. Helgetveit Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients Acta Neurol Scand 93 1996 14 20
34. W.C. Koller, J.T. Hutton, E. Tolosa, R. Capildeo T.C.L.S. Group Immediate-release and controlled-release carbidopa/levodopa in Parkinson's disease. A 5-year randomized multicenter study Neurology 53 1999 1012 1019
35. C. Colosimo, and M. De Michele Motor fluctuations in Parkinson's disease: pathophysiology and treatment Eur J Neurol 6 1 1999 1 21
36. Parkinson Study group Levodopa and the progression of Parkinson's disease N Engl J Med 351 24 2005 2498 2508
37. V. Bonifati, and G. Meco New, selective catechol-O-methyltransferase inhibitors as therapeutic agents in Parkinson's disease Pharmacol Ther 81 1 1999 1 36
38. F. Assal, L. Spahr, A. Hadengue, L. Rubbia-Brandt, P.R. Burkhard, and L. Rubbici-Brandt Tolcapone and fulminant hepatitis Lancet 352 9132 1998 958
39. C.W. Olanow Tolcapone and hepatotoxic effects. Tasmar Advisory Panel Arch Neurol 57 2 2000 263 267
40. V.V. Myllyla, E.R. Kultalahti, H. Haapaniemi, and M. Leinonen Twelve-month safety of entacapone in patients with Parkinson's disease Eur J Neurol 8 1 2001 53 60
41. Parkinson Study group Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients Ann Neurol 42 5 1997 747 755
42. U.K. Rinne, J.P. Larsen, A. Siden, J. Worm-Petersen Nomecomt Study Group Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations Neurology 51 5 1998 1309 1314
43. F. Durif, I. Devaux, J.J. Pere, J.C. Delumeau, and I. Bourdeix Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study Eur Neurol 45 2 2001 111 118
44. W.H. Poewe, G. Deuschl, A. Gordin, E.R. Kultalahti, and M. Leinonen Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study) Acta Neurol Scand 105 4 2002 245 255
45. J.P. Larsen, J. Worm-Petersen, A. Siden, A. Gordin, K. Reinikainen, and M. Leinonen The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease Eur J Neurol 10 2 2003 137 146
46. G. Fenelon, S. Gimenez-Roldan, J.L. Montastruc, F. Bermejo, F. Durif, and I. Bourdeix Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study J Neural Transm 110 3 2003 239 251
47. D.J. Brooks, and H. Sagar Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study J Neurol Neurosurg Psychiatr 74 8 2003 1071 1079
48. C.H. Waters, K.D. Sethi, R.A. Hauser, E. Molho, and J. Bertoni Zydis selegiline reduces off time in Parkinson's disease patients with mototr fluctuations: a 3-month, randomized, placebo-controlled study Mov Disord 19 4 2004 426 432
49. A. Churchyard, C.J. Mathias, P. Boonkongchuen, and A.J. Lees Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease J Neurol Neurosurg Psychiatr 63 2 1997 228 234
50. Lees Parkinson's Disease Research Group of the United Kingdom Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease Br Med J 311 1995 1602 1607
51. Y. Ben-Shlomo, and K. Bhatia Using monoamine oxidase type B inhibitors in Parkinson's disease BMJ 329 2004 581 582
52. Parkinson study group A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease Arch Neurol 61 4 2004 561 566
53. M.B. Stern, K.L. Marek, J. Friedman, R.A. Hauser, P.A. LeWitt, and D. Tarsy Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients Mov Disord 19 8 2004 916 923
54. R.S. Schwab, L.V. Amador, and J.Y. Lettvin Apomorphine in Parkinson's disease Trans Am Neurol Assoc 56 1951 251 253
55. R.J. McDonald, and R. Horowski Lisuride in the treatment of parkinsonism Eur Neurol 22 4 1983 240 255
56. M.M. Hoehn, and R.L. Elton Low dosages of bromocriptine added to levodopa in Parkinson's disease Neurology 35 2 1985 199 206
57. A.L. Whone, R.L. Watts, A.J. Stoessl, M. Davis, S. Reske, and C. Nahmias Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study Ann Neurol 54 1 2003 93 101
58. Parkinson stuy group Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression JAMA 287 13 2002 1653 1661
59. N. Ogawa, K. Tanaka, M. Asanuma, M. Kawai, T. Masumizu, and M. Kohno Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res 657 1-2 1994 207 213
60. P.P. Michel, and F. Hefti Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture J Neurosci Res 26 4 1990 428 435
61. P.M. Carvey, S. Pieri, and Z.D. Ling Attenuation of levodopa-induced toxicity in mesenphalic cultures by pramipexole J Neural Transm 104 1997 209 228
62. J.E. Ahlskog Slowing Parkinson's disease progression: recent dopamine agonist trials Neurology 60 3 2003 381 389
63. C. Mytilineou, R.H. Walker, R. JnoBaptiste, and C.W. Olanow Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress J Pharmacol Exp Ther 304 2 2003 792 800
64. M.J. Millan, L. Maiofiss, D. Cussac, V. Audinot, J.A. Boutin, and A. Newman-Tancredi Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes J Pharmacol Exp Ther 303 2 2002 791 804
65. Parkinson study group Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial JAMA 284 15 2000 1931 1938
66. U.K. Rinne, F. Bracco, C. Chouza, E. Dupont, O. Gershanik, and J.F. Marti Mosso Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial Drugs 55 1998 S23 S30
67. P. Barone, D. Bravi, F. Bermejo-Pareja, R. Marconi, J. Kulisevsky, S. Malagu Pergolide monotherapy study group Pergolide monotherapy in the treatment of early PD: a randomized, controlled study Neurology 53 1999 573 579
68. A.N. Lieberman, A. Neophytides, M. Leibowitz, G. Gopinathan, V. Pact, and R. Walker Comparative efficacy of pergolide and bromocriptine in patients with advanced Parkinson's disease Adv Neurol 37 1983 95 108
69. G. Pezzoli, E. Martignoni, C. Pacchetti, V. Angeleri, P. Lamberti, and A. Muratorio A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease Neurology 45 3 Suppl. 3 1995 S22 S27
70. R. Inzelberg, P. Nisipeanu, J.M. Rabey, E. Orlov, T. Catz, and S. Kippervasser Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations Neurology 47 3 1996 785 788
71. M. Guttman International, Pramipexole-, Bromocriptine, Study, and Group Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease Neurology 49 1997 1060 1065
72. E.R. Brunt, D.J. Brooks, A.D. Korczyn, J.L. Montastruc, and F. Stocchi A 6-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa J Neural Transm 109 4 2002 489 502
73. M. Ziegler, A. Castro-Caldas, S. Del Signore, and O. Rascol Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study Mov Disord 18 4 2003 418 425
74. A. Lieberman, C.W. Olanow, K. Sethi, P. Swanson, C.H. Waters, S. Fahn Ropinirole study group A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease Neurology 51 4 1998 1057 1062
75. G.C. Cotzias, P.S. Papavasiliou, C. Fehling, B. Kaufman, and I. Mena Similarities between neurologic effects of L-dipa and of apomorphine N Engl J Med 282 1 1970 31 33
76. L. Ostergaard, L. Werdelin, P. Odin, O. Lindvall, E. Dupont, and P.B. Christensen Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study J Neurol Neurosurg Psychiatr 58 6 1995 681 687
77. K. Pietz, P. Hagell, and P. Odin Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up J Neurol Neurosurg Psychiatr 65 5 1998 709 716
78. J.H. Friedman, S.S. Feinberg, and R.G. Feldman A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal JAMA 254 19 1985 2792 2795
79. E. Broussolle, M.H. Marion, and P. Pollak Continuous subcutaneous apomorphine as replacement for levodopa in severe parkinsonian patients after surgery Lancet 340 8823 1992 859 860
80. C.E. Clarke, and K.H. Deane Ropinirole for levodopa-induced complications in Parkinson's disease Cochrane Database Syst Rev 1 2001 CD001516
81. C.E. Clarke, and K.H. Deane Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease Cochrane Database Syst Rev 1 2001 001517
82. E.K. Tan, P. Ratnagopal, S.Y. Han, and M.C. Wong Piribedil and bromocriptine in Parkinson's disease: a single-blind crossover study Acta Neurol Scand 107 3 2003 202 206
83. C.E. Clarke, and K.D. Deane Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease Cochrane Database Syst Rev 1 2001 001519
84. R. Inzelberg, E. Schechtman, and P. Nisipeanu Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison Drugs Aging 20 11 2003 847 855
85. M. Canesi, A. Antonini, C.B. Mariani, S. Tesei, A.L. Zecchinelli, and M. Barichella An overnight switch to ropinirole therapy in patients with Parkinson's disease. Short communication J Neural Transm 106 9-10 1999 925 929
86. P.A. LeWitt, G. Gopinathan, C.D. Ward, J.N. Sanes, J.M. Dambrosia, and R. Durso Lisuride versus bromocriptine treatment in Parkinson disease: a double-blind study Neurology 32 1 1982 69 72
87. M.J. Vidailhet, A.M. Bonnet, S. Belal, B. Dubois, C. Marle, and Y. Agid Ropinirole without levodopa in Parkinson's disease Lancet 336 8710 1990 316 317
88. S. Gimenez-Roldan, E.M. Esteban, and D. Mateo Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios Clin Neuropharmacol 24 6 2001 346 351
89. H. Reichmann, B. Herting, A. Miller, and U. Sommer Switching and combining dopamine agonists J Neural Transm 110 12 2003 1393 1400
90. J.G. Nutt L-DOPA-induced dyskinesias: review, observations and speculations Neurology 40 1990 340 345
91. F. Calon, R. Grondin, M. Morissette, M. Goulet, P.J. Blanchet, and T. Di Paolo Molecular basis of levodopa-induced dyskinesias Ann Neurol 47 4 Suppl. 1 2000 S70 S78
92. P. Damier, L. Tremblay, J. Feger, and E.C. Hirsch [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)] Rev Neurol (Paris) 156 3 2000 224 235
93. A. Destee Parkinson's disease: what therapeutic strategy is advisable in early stage disease? Rev Neurol (Paris) 156 Suppl. 2 Pt 2 2000 109 118
94. S. Shaunak, A. Wilkins, J.B. Pilling, and D.J. Dick Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide J Neurol Neurosurg Psychiatr 66 1 1999 79 81
95. O. Rascol Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease J Neural Transm 55 1999 33 45
96. J.A. Saint-Cyr, A.E. Taylor, and A.E. Lang Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease Neurology 43 12 Suppl. 6 1993 S47 S52
97. S. Frucht, J.D. Rogers, P.E. Greene, M.F. Gordon, and S. Fahn Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole Neurology 52 9 1999 1908 1910
98. J.L. Montastruc, C. Brefel-Courbon, J.M. Senard, H. Bagheri, J. Ferreira, and O. Rascol Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study Clin Neuropharmacol 24 3 2001 181 183
99. P.E. O'Suilleabhain, and R.B. Dewey Jr. Contributions of dopaminergic drugs and disease severity to daytime sleepiness in Parkinson disease Arch Neurol 59 6 2002 986 989
100. I. Arnulf, E. Konofal, M. Merino-Andreu, J.L. Houeto, V. Mesnage, and M.L. Welter Parkinson's disease and sleepiness: an integral part of PD Neurology 58 7 2002 1019 1024
101. P.J. Blanchet, L.V. Metman, and T.N. Chase Renaissance of amantadine in the treatment of Parkinson's disease Adv Neurol 91 2003 251 257
102. L.V. Metman, P. Del Dotto, K. LePoole, S. Konitsiotis, J. Fang, and T.N. Chase Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study Arch Neurol 56 11 1999 1383 1386
103. A. Thomas, D. Iacono, A.L. Luciano, K. Armellino, A. Di Iorio, and M. Onofrj Duration of amantadine benefit on dyskinesia of severe Parkinson's disease J Neurol Neurosurg Psychiatr 75 1 2004 141 143
104. W.H. Timberlake Double-blind comparison of levodopa and procyclidine in parkinsonism, with illustrations of levodopa-induced movement disorders Neurology 20 1970 31 35
105. W. Koller Pharmacologic treatment of parkinsonian tremor Arch Neurol 43 1986 126 127
106. W.W. Tourtelotte, A.R. Potvin, K. Syndulko, S.B. Hirsch, E.R. Gilden, and J.H. Potvin Parkinson's disease: cogentin with sinamet, a better response Prog Neuropsychopharmacol Biol Psychiatr 6 1982 51 55
107. Katzenschlager R, Sampaio C, Costa J, Lees AJ, Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev, 2003;2.
108. I. Cooper Surgical alleviation of Parkinsonism: effects of occlusion of the anterior choroidal artery J Am Geriatr Soc 2 1954 691 718
109. R. Hassler, and T. Riechert Indications and localization of stereotactic brain operations Nervenarzt 25 11 1954 441 447
110. L.V. Laitinen, A.T. Bergenheim, and M.I. Hariz Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease J Neurosurg 76 1 1992 53 61
111. E. Svennilson, A. Torvik, R. Lowe, and L. Leksell Treatment of parkinsonism by stereotatic thermolesions in the pallidal region. A clinical evaluation of 81 cases Acta Psychiatr Scand 35 1960 358 377
112. M.S. Baron, J.L. Vitek, R.A. Bakay, J. Green, Y. Kaneoke, and T. Hashimoto Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study Ann Neurol 40 3 1996 355 366
113. A.E. Lang, A.M. Lozano, E. Montgomery, J. Duff, R. Tasker, and W. Hutchinson Posteroventral medial pallidotomy in advanced Parkinson's disease N Engl J Med 337 15 1997 1036 1042
114. R.M. de Bie, R.J. de Haan, P.C. Nijssen, A.W. Rutgers, G.N. Beute, and D.A. Bosch Unilateral pallidotomy in Parkinson's disease: a randomised, single-blind, multicentre trial Lancet 354 9191 1999 1665 1669
115. J. Fine, J. Duff, R. Chen, B. Chir, W. Hutchison, and A.M. Lozano Long-term follow-up of unilateral pallidotomy in advanced Parkinson's disease N Engl J Med 342 23 2000 1708 1714
116. J.L. Vitek, R.A. Bakay, A. Freeman, M. Evatt, J. Green, and W. McDonald Randomized trial of pallidotomy versus medical therapy for Parkinson's disease Ann Neurol 53 5 2003 558 569
117. M.I. Hariz, and A.T. Bergenheim A 10-year follow-up review of patients who underwent Leksell's posteroventral pallidotomy for Parkinson disease J Neurosurg 94 4 2001 552 558
118. M.S. Baron, J.L. Vitek, R.A. Bakay, J. Green, W.M. McDonald, and S.A. Cole Treatment of advanced Parkinson's disease by unilateral posterior GPi pallidotomy: 4-year results of a pilot study Mov Disord 15 2 2000 230 237
119. R.M. de Bie, R.J. de Haan, P.R. Schuurman, R.A. Esselink, D.A. Bosch, and J.D. Speelman Morbidity and mortality following pallidotomy in Parkinson's disease: a systematic review Neurology 58 7 2002 1008 10012
120. T. Hirai, M. Miyazaki, H. Nakajima, T. Shibazaki, and C. Ohye The correlation between tremor characteristics and the predicted volume of effective lesions in stereotaxic nucleus ventralis intermedius thalamotomy Brain 106 Pt 4 1983 1001 1018
121. C. Ohye, T. Shibazaki, M. Hirato, Y. Kawashima, and M. Matsumura Strategy of selective VIM thalamotomy guided by microrecording Stereotact Funct Neurosurg 54-55 1990 186 191
122. P.R. Schuurman, D.A. Bosch, P.M. Bossuyt, G.J. Bonsel, E.J. van Someren, and R.M. de Bie A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor N Engl J Med 342 7 2000 461 468
123. D.D. Webster Dynamic evaluation of thalamotomyin Parkinson's disease: analysis of 75 consecutive cases F.J. Gillingham I.M.L. Donaldson Proceedings of the Third Symposium on Parkinson's Disease Edinburgh, Livingstone, London 1969 266 271
124. K. Matsumoto, F. Shichijo, and T. Fukami Long-term follow-up review of cases of Parkinson's disease after unilateral or bilateral thalamotomy J Neurosurg 60 5 1984 1033 1044
125. O.J. Andy, M.F. Jurko, and F.R. Sias Jr. Subthalamotomy in Treatment of Parkinsonian Tremor J Neurosurg 20 1963 860 870
126. R.L. Albin, A.B. Young, and J.B. Penney The functional anatomy of basal ganglia disorders Trends Neurosci 12 10 1989 366 375
127. H. Bergman, T. Wichmann, and M.R. DeLong Reversal of experimental parkinsonism by lesions of the subthalamic nucleus Science 249 4975 1990 1436 1438
128. S.S. Gill, and P. Heywood Bilateral dorsolateral subthalamotomy for advanced Parkinson's disease Lancet 350 9086 1997 1224
129. N.K. Patel, P. Heywood, K. O'Sullivan, R. McCarter, S. Love, and S.S. Gill Unilateral subthalamotomy in the treatment of Parkinson's disease Brain 126 Pt 5 2003 1136 1145
130. A.L. Benabid, P. Pollak, A. Louveau, S. Henry, and J. de Rougemont Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease Appl Neurophysiol 50 1-6 1987 344 346
131. D. Caparros-Lefebvre, S. Blond, P. Vermersch, N. Pecheux, J.D. Guieu, and H. Petit Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson's disease J Neurol Neurosurg Psychiatr 56 3 1993 268 273
132. F. Alesch, M.M. Pinter, R.J. Helscher, L. Fertl, A.L. Benabid, and W.T. Koos Stimulation of the ventral intermediate thalamic nucleus in tremor dominated Parkinson's disease and essential tremor Acta Neurochir (Wien) 136 1-2 1995 75 81
133. W. Koller High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor Ann Neurol 42 3 1997 292 299
134. P. Limousin, P. Pollak, A. Benazzouz, D. Hoffmann, J.F. Le Bas, and E. Broussolle Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation Lancet 345 8942 1995 91 95
135. R. Kumar, A.M. Lozano, E. Montgomery, and A.E. Lang Pallidotomy and deep brain stimulation of the pallidum and subthalamic nucleus in advanced Parkinson's disease Mov Disord 13 Suppl. 1 1998 73 82
136. P. Krack, P. Pollak, P. Limousin, D. Hoffmann, J. Xie, and A. Benazzouz Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease Brain 121 Pt 3 1998 451 457
137. P. Krack, A. Batir, N. Van Blercom, S. Chabardes, V. Fraix, and C. Ardouin Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease N Engl J Med 349 20 2003 1925 1934
138. E. Moro, M. Scerrati, L.M. Romito, R. Roselli, P. Tonali, and A. Albanese Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease Neurology 53 1 1999 85 90
139. J.L. Houeto, P. Damier, P.B. Bejjani, C. Staedler, A.M. Bonnet, and I. Arnulf Subthalamic stimulation in Parkinson disease: a multidisciplinary approach Arch Neurol 57 4 2000 461 465
140. F.J. Vingerhoets, J.G. Villemure, P. Temperli, C. Pollo, E. Pralong, and J. Ghika Subthalamic DBS replaces levodopa in Parkinson's disease: 2-year follow-up Neurology 58 3 2002 396 401
141. S. Thobois, P. Mertens, M. Guenot, M. Hermier, H. Mollion, and M. Bouvard Subthalamic nucleus stimulation in Parkinson's disease: clinical evaluation of 18 patients J Neurol 249 5 2002 529 534
142. V. Fraix, P. Pollak, N. Van Blercom, J. Xie, P. Krack, and A. Koudsie Effect of subthalamic nucleus stimulation on levodopa-induced dyskinesia in Parkinson's disease Neurology 55 12 2000 1921 1923
143. J. Volkmann, N. Allert, J. Voges, P.H. Weiss, H.J. Freund, and V. Sturm Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD Neurology 56 4 2001 548 551
144. R.A. Esselink, R.M. de Bie, R.J. de Haan, M.W. Lenders, P.C. Nijssen, and M.J. Staal Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial Neurology 62 2 2004 201 207
145. C. Ardouin, B. Pillon, E. Peiffer, P. Bejjani, P. Limousin, and P. Damier Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: a consecutive series of 62 patients Ann Neurol 46 2 1999 217 223
146. J.A. Saint-Cyr, L.L. Trepanier, R. Kumar, A.M. Lozano, and A.E. Lang Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease Brain 123 Pt 10 2000 2091 2108
147. J. Siegfried, and B. Lippitz Chronic electrical stimulation of the VL-VPL complex and of the pallidum in the treatment of movement disorders: personal experience since Stereotact Funct Neurosurg 62 1-4 1994 71 75
148. J. Volkmann, V. Sturm, P. Weiss, J. Kappler, J. Voges, and A. Koulousakis Bilateral high-frequency stimulation of the internal globus pallidus in advanced Parkinson's disease Ann Neurol 44 6 1998 953 961
149. K.J. Burchiel, V.C. Anderson, J. Favre, and J.P. Hammerstad Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study Neurosurgery 45 6 1999 1375 1382 discussion 1382-1384
150. Deep-Brain Stimulation for Parkinson's Disease study group Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease N Engl J Med 345 2001 956 963
151. J.L. Houeto, P.B. Bejjani, P. Damier, C. Staedler, A.M. Bonnet, and B. Pidoux Failure of long-term pallidal stimulation corrected by subthalamic stimulation in PD Neurology 55 5 2000 728 730
152. B. Bejjani, P. Damier, I. Arnulf, A.M. Bonnet, M. Vidailhet, and D. Dormont Pallidal stimulation for Parkinson's disease. Two targets? Neurology 49 6 1997 1564 1569
153. H. Bernheimer, W. Birkmayer, O. Hornykiewicz, K. Jellinger, and F. Seitelberger Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations J Neurol Sci 20 4 1973 415 455
154. M.J. Perlow, W.J. Freed, B.J. Hoffer, A. Seiger, L. Olson, and R.J. Wyatt Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system Science 204 4393 1979 643 647
155. P. Brundin, R.E. Strecker, H. Widner, D.J. Clarke, O.G. Nilsson, and B. Astedt Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: immunological aspects, spontaneous and drug-induced behaviour, and dopamine release Exp Brain Res 70 1 1988 192 208
156. O. Lindvall, H. Widner, S. Rehncrona, P. Brundin, P. Odin, and B. Gustavii Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants Ann Neurol 31 2 1992 155 165
157. G.V. Sawle, P.M. Bloomfield, A. Bjorklund, D.J. Brooks, P. Brundin, and K.L. Leenders Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants Ann Neurol 31 2 1992 166 173
158. M. Peschanski, G. Defer, J.P. N'Guyen, F. Ricolfi, J.C. Monfort, and P. Remy Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon Brain 117 Pt 3 1994 487 499
159. J.H. Kordower, T.B. Freeman, B.J. Snow, F.J. Vingerhoets, E.J. Mufson, and P.R. Sanberg Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease N Engl J Med 332 17 1995 1118 1124
160. P. Piccini, D.J. Brooks, A. Bjorklund, R.N. Gunn, P.M. Grasby, and O. Rimoldi Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient Nat Neurosci 2 12 1999 1137 1140
161. P. Piccini, O. Lindvall, A. Bjorklund, P. Brundin, P. Hagell, and R. Ceravolo Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts Ann Neurol 48 5 2000 689 695
162. C.R. Freed, P.E. Greene, R.E. Breeze, W.Y. Tsai, W. DuMouchel, and R. Kao Transplantation of embryonic dopamine neurons for severe Parkinson's disease N Engl J Med 344 10 2001 710 719
163. C.W. Olanow, C.G. Goetz, J.H. Kordower, A.J. Stoessl, V. Sossi, and M.F. Brin A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease Ann Neurol 54 3 2003 403 414
164. P. Hagell, P. Piccini, A. Bjorklund, P. Brundin, S. Rehncrona, and H. Widner Dyskinesias following neural transplantation in Parkinson's disease Nat Neurosci 5 7 2002 627 628
165. J.S. Fink Porcine xenografts in Parkinson's disease and Huntington's disease patients: preliminary results Cell Transplant 9 2 2000 273 278
166. O. Lindvall Stem cells for cell therapy in Parkinson's disease Pharmacol Res 47 4 2003 279 287
167. L.F. Lin, D.H. Doherty, J.D. Lile, S. Bektesh, and F. Collins GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons Science 260 5111 1993 1130 1132
168. A. Tomac, E. Lindqvist, L.F. Lin, S.O. Ogren, D. Young, and B.J. Hoffer Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo Nature 373 6512 1995 335 339
169. R. Grondin, Z. Zhang, A. Yi, W.A. Cass, N. Maswood, and A.H. Andersen Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys Brain 125 Pt 10 2002 2191 2201
170. J.G. Nutt, K.J. Burchiel, C.L. Comella, J. Jankovic, A.E. Lang, and E.R. Laws Jr. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD Neurology 60 1 2003 69 73
171. S.S. Gill, N.K. Patel, G.R. Hotton, K. O'Sullivan, R. McCarter, and M. Bunnage Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease Nat Med 9 5 2003 589 595